Fingolimod
- PDF / 169,426 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 79 Downloads / 147 Views
1 S
Bradycardia and lymphopenia during off-label use: 2 case reports In a retrospective, open-label, observational study of 22 patients with relapsing-remitting multiple sclerosis (RRMS), who received treatment with fingolimod in Turkey between February 2015 and December 2018 when they were aged below 18 years, 2 boys including one child [exact ages not stated] were described, who developed bradycardia or lymphopenia during the off-label treatment with fingolimod for RRMS [routes and duration of treatments to reactions onsets not stated]. The boy with RRMS, started receiving off-label treatment with fingolimod capsules 0.5 mg/day. At the first dose, his minimum HR was 53 /minute and 58 /minute at the sixth hour. During the follow-up, his bradycardia disappeared. At the time of last follow-up, he was 13-years old. A male child with RRMS, started receiving off-label treatment with fingolimod capsules 0.5 mg/day. Subsequently, his lymphocyte count decreased to 200 /mm3 consistent with lymphopenia; hence, the dose of fingolimod was changed to 0.5mg every other day. He remained stable under this treatment. Ilki CD, et al. Fingolimod therapy for pediatric relapsing-remitting multiple sclerosis: A real-life study. Turk Noroloji Dergisi 26: 34-38, No. 1, Mar 2020. Available from: 803497696 URL: http://doi.org/10.4274/tnd.galenos.2019.77010
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
